10-Q · May 16, 2026
Estrella Immunopharma's Q1 2026 10-Q reveals continued financial challenges, with no reported revenue and an increase in net loss to approximately $2.3 million from $2.1 million in the prior year. Cash and cash…
Earnings analysis · 10-Q
ESLA earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include the financial statements or MD&A, so revenue, margins, EPS, liquidity, cash flow, and segment trends cannot be quantified. The principal update is that disclosure controls…
Read full summary
The provided 10-Q excerpt does not include the financial statements or MD&A, so revenue, margins, EPS, liquidity, cash flow, and segment trends cannot be quantified. The principal update is that disclosure controls remained ineffective as of June 30, 2026 due to a material weakness involving qualified accounting personnel, despite remediation efforts implemented during 2025 and 2024. No material changes to the previously disclosed risk factors were reported.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control Remediation Efforts Continued
Management reports that remediation efforts for prior control weaknesses took place during 2025 and 2024, including adding qualified accounting personnel and implementing additional review processes.
-
No New Control Changes Reported
The filing states there were no changes during the three months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
Material Weakness Remains
Disclosure controls and procedures were not effective at a reasonable-assurance level as of June 30, 2026 because the company lacked qualified full-time personnel with appropriate accounting knowledge and experience for complex GAAP matters.
-
Existing 10-K Risks Continue
The company states that there were no material changes to the risk factors disclosed in its Annual Report on Form 10-K filed March 18, 2026; those existing risks remain applicable and could materially affect results or financial condition.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue, EPS, cash-flow, or operating outlook. No explicit guidance was provided; management states only that the company is not required to provide market-risk disclosures under Item 3.
Earlier filings 4
10-K · April 30, 2026
Estrella Immunopharma continues to advance its T-cell therapy program but faces significant liquidity challenges, holding approximately $1.4 million in cash. The company recently completed the Phase I dose escalation in…
10-K · March 18, 2026
Estrella Immunopharma is a clinical-stage T‑cell therapy company advancing its lead ARTEMIS® program, EB103, which completed Phase I dose escalation (n=9) and moved into a Phase II expansion at the recommended Phase II…
10-Q · May 15, 2024
Estrella reported no revenue and a Q3 net loss of $469,530 ($(0.01) per share), a material improvement from the prior-year quarter net loss of $2,741,106 ($(8.13) per share). Cash increased to $4.73 million as of March…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.